Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 Feb 25;57(4):569–577. doi: 10.1002/pbc.22944

Figure 4.

Figure 4

Cumulative incidence of marrow (A) and non-marrow (B) relapse of patients based on end of induction MRD status. Patients with at least .01% marrow MRD had a nearly 4 fold increased risk of marrow relapse at 5 years, at 48.8±5.8% compared to 13.0±2.8% for those who were MRD negative. The 5 year cumulative incidence of non marrow relapse was 12% in both the MRD positive and negative groups.